[go: up one dir, main page]

MX2010004671A - Seprasa como marcador para cancer. - Google Patents

Seprasa como marcador para cancer.

Info

Publication number
MX2010004671A
MX2010004671A MX2010004671A MX2010004671A MX2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A
Authority
MX
Mexico
Prior art keywords
cancer
seprase
types
lung
evaluation
Prior art date
Application number
MX2010004671A
Other languages
English (en)
Inventor
Michael Tacke
Johann Karl
Markus Roessler
Wolfgang Rollinger
Jarema Peter Kochan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010004671A publication Critical patent/MX2010004671A/es

Links

Classifications

    • G01N33/5752—
    • G01N33/57535—
    • G01N33/57557—
    • G01N33/57565—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para ayudar en la evaluación del cáncer. Describe el uso de la proteína de activación de fibroblasto humana (FAP/seprasa) como un marcador universal de diferentes tipos de cáncer. La seprasa ayuda en la evaluación de cáncer pulmonar o de pulmón (LC) o cáncer de colon, por ejemplo, carcinoma de pulmón de célula no pequeña (NSCLC) o cáncer colorrectal (CRC), pero también probablemente de otros tipos de cáncer específico. Tales tipos de cáncer específicos son por ejemplo cáncer esófago, cabeza y cuello, cáncer de estómago, cáncer de los conductos biliares, cáncer pancreático, cáncer de riñón, cáncer cervicouterino, cáncer ovárico, cáncer de pecho, cáncer de vejiga, cáncer del endometrio o cáncer de próstata. Además, especialmente se refiere a un método para evaluar el cáncer de una muestra líquida, derivada de un individuo mediante la medición de seprasa en la muestra. La medición de seprasa puede, por ejemplo, utilizarse en la detección temprana de cáncer o en la supervivencia de pacientes que han experimentado cirugía.
MX2010004671A 2007-12-10 2008-12-08 Seprasa como marcador para cancer. MX2010004671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
MX2010004671A true MX2010004671A (es) 2010-05-27

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004671A MX2010004671A (es) 2007-12-10 2008-12-08 Seprasa como marcador para cancer.

Country Status (14)

Country Link
US (1) US8980573B2 (es)
EP (1) EP2223115B1 (es)
JP (1) JP5563988B2 (es)
KR (1) KR101202220B1 (es)
CN (1) CN101896818B (es)
AT (1) ATE524740T1 (es)
AU (1) AU2008335855B2 (es)
BR (1) BRPI0820793A2 (es)
CA (1) CA2706115A1 (es)
DK (1) DK2223115T3 (es)
ES (1) ES2372442T3 (es)
MX (1) MX2010004671A (es)
PL (1) PL2223115T3 (es)
WO (1) WO2009074275A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
EP2297581B1 (en) * 2008-07-03 2013-04-03 F. Hoffmann-La Roche AG Asc as a marker for lung cancer
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ700695A (en) 2010-02-05 2016-05-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6026422B2 (ja) * 2010-10-20 2016-11-16 ラッシュ ユニバーシティ メディカル センターＲｕｓｈ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 肺がん試験
CA2826820A1 (en) * 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
CA2826838A1 (en) * 2011-03-11 2012-09-20 F.Hoffmann-La Roche Ag Seprase as marker for chronic obstructive pulmonary disease (copd)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
MX360236B (es) 2012-06-27 2018-10-26 Berg Llc Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
KR20150090240A (ko) * 2012-11-30 2015-08-05 어플라이드 프로테오믹스, 인크. 결장 종양의 존재 또는 위험의 평가 방법
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
US10365281B2 (en) 2013-12-09 2019-07-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
CN107428821B (zh) 2014-12-08 2022-06-24 博格有限责任公司 包括细丝蛋白a的标志物在诊断和治疗前列腺癌中的用途
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
WO2018020530A1 (ja) * 2016-07-25 2018-02-01 静岡県 肝外胆管癌、肝内胆管癌、又は胆嚢癌の診断用バイオマーカー
ES2972577T3 (es) 2016-12-14 2024-06-13 Purdue Research Foundation Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP)
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
CA3074684A1 (en) * 2017-09-05 2019-03-14 Oncotag Diagnostics Co., Ltd. Method for diagnosing pancreatic cancer using methionyl-trna synthetase, and pancreatic cancer diagnostic kit using same
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CN104531529A (zh) * 2003-10-31 2015-04-22 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
JP2008517914A (ja) * 2004-10-22 2008-05-29 ジェネンコー・インターナショナル・インク ヒトの抗体の分離方法
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
KR20150003157A (ko) * 2005-12-19 2015-01-08 트러스티즈 오브 터프츠 칼리지 소프트 단백질분해효소 억제자 및 이의 프로-소프트 폼

Also Published As

Publication number Publication date
AU2008335855A1 (en) 2009-06-18
ATE524740T1 (de) 2011-09-15
JP5563988B2 (ja) 2014-07-30
EP2223115A1 (en) 2010-09-01
KR101202220B1 (ko) 2012-11-16
US8980573B2 (en) 2015-03-17
HK1150884A1 (zh) 2012-01-13
DK2223115T3 (da) 2011-12-12
BRPI0820793A2 (pt) 2015-06-16
CA2706115A1 (en) 2009-06-18
PL2223115T3 (pl) 2012-02-29
EP2223115B1 (en) 2011-09-14
JP2011506941A (ja) 2011-03-03
WO2009074275A1 (en) 2009-06-18
US20100240081A1 (en) 2010-09-23
CN101896818B (zh) 2016-01-20
KR20100091212A (ko) 2010-08-18
AU2008335855B2 (en) 2012-08-30
CN101896818A (zh) 2010-11-24
ES2372442T3 (es) 2012-01-19

Similar Documents

Publication Publication Date Title
MX2010004671A (es) Seprasa como marcador para cancer.
WO2010072383A8 (en) Armet as a marker for cancer
ATE554389T1 (de) Apex als marker für lungenkrebs
IN2012DN01708A (es)
ES2683362T3 (es) Microvesículas obtenidas a partir de células tumorales
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
IL201778A0 (en) Peptide imaging agents
WO2010136163A8 (en) Secernin-1 as a marker for cancer
WO2011086174A3 (en) Diagnostic gene expression platform
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
NZ621733A (en) Lung cancer biomarkers and uses thereof
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
WO2014026768A8 (en) Colorectal cancer markers
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
AR083357A1 (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama
WO2009143181A3 (en) Micro-rna profile in human saliva and its use for detection of oral cancer
MX2012007940A (es) Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer
MX369763B (es) Sistemas y metodos de codificacion para la calibracion de biosensores.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
WO2011163627A3 (en) Organ specific diagnostic panels and methods for identification of organ specific panel proteins
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom

Legal Events

Date Code Title Description
FG Grant or registration